Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat domain 20 (WDR20) is a member of the WD repeat domain protein family characterized by several WD40 motifs that enable protein-protein interactions through a β-propeller structure[1][2]. WDR20 acts as a regulatory subunit that preserves and modulates the activity of the USP12-UAF1 deubiquitinating enzyme complex, which is involved in removing ubiquitin from target proteins and regulating their stability and localization[2]. WDR20 anchors USP12 at the base of its ubiquitin-contacting loop and allosterically influences the catalytic center, controlling the deubiquitination process. It shuttles the USP12 complex between the plasma membrane, cytoplasm, and nucleus[2]. Diseases associated with mutations in the WDR20 gene include Temple syndrome and Mulchandani-Bhoj-Conlin syndrome[2]. WDR20 does not have direct small molecule modulators currently known in clinical use or development, but its role as a scaffold and regulator of deubiquitinating complexes makes it of emerging interest in pathways relevant to cancer and protein homeostasis[2][3].
Modulation of deubiquitination via activation/regulation of USP12-UAF1 complexes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat domain 20 (WDR20).